The NECT Story
About Sleeping Sickness
NECT: Contributions to Its Success
ANECT: Other Studies
HAT Regional Network
NECT: challenges in The Field
Patient’s Story
Sailing Away
Brief News
DND<em>i</em>’s HAT-Related News

Nifurtimox-Eflornithine Combination Therapy:
An Improved Treatment for Sleeping Sickness
The NECT Phase III pivotal study conclusively demonstrates that the coadministration of oral nifurtimox and intravenous eflornithine (NECT) is a safe, effective treatment for stage 2 HAT patients, and more practical than eflornithine monotherapy.
Background: the need for combination therapies for stage 2 HAT
The rationale for the NECT (nifurtimoxeflornithine combination therapy) study lies in the fact that, for stage 2 HAT, there were few available drugs, each with serious limitations (see on existing treatments)
Sleeping Sickness
[Human African Trypanosomiasis - HAT]
60 million people at risk in sub-Saharan Africa
What is the annual impact of HAT?
50,000-70,000 cases(1)
1,525,000 DALYs(2) (3)

Large proportions of communities can be affected by HAT, with serious social and economic consequences....
TDR investigates NECT in Uganda
As part of a larger collaborative effort with DNDi and Epicentre, the TDR has sponsored a clinical trial comparing the NECT combination with the standard eflornithine regimen for the treatment....
Challenges of Establishing and Monitoring a GCP Trial in Remote Settings
Working in rural areas such as the NECT trial sites in Dipumba and Katanda in the Democratic Republic of the Congo (DRC), researchers face many challenges that do not exist in other settings. ...
Thank you Angèle
One key team member of the NECT study was Angèle Ngo-On, who provided logistical support from November 2005 through August 2008...
HAT Projects Supported by Public and Private Funds
Thanks to continuous support from our public and private donors, from 2003 to 2008 DNDi has disbursed EUR 16.5 million for its portfolio of human African trypanosomiasis (HAT) projects.
The Key Role Played by the HAT Platform
Built around the national HAT control programmes of the most affected countries, the HAT Platform is a regional network to strengthen research capacity on human African trypanosomiasis (HAT)...
A Hope for Surviving Sleeping Sickness: Joseph’s Story
Sleeping sickness (HAT) has accompanied the Mutombo family for the past two years. Alongside his mother, Joseph is resting tiredly at a specialised treatment centre after they underwent painful lumbar punctures...
Fexinidazole Progresses into Clinical Development
In early 2009, DNDi plans to advance fexinidazole into first-in-human, Phase I studies. Fexinidazole is the first compound to be taken by DNDi...
Published by Drugs for Neglected Diseases Initiative - 15 Chemin Louis-Dunant 1202 Geneva Switzerland - Photo credits: DNDi unless otherwise stated - Editor: Sadia Kaenzig - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 -